Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study - PubMed (original) (raw)

doi: 10.1002/hep.510250344.

E Silini, A Crosignani, F Borzio, G Leandro, F Bono, M Asti, S Rossi, A Larghi, A Cerino, M Podda, M U Mondelli

Affiliations

• PMID: 9049231
• DOI: 10.1002/hep.510250344

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

S Bruno et al. Hepatology. 1997 Mar.

Abstract

A prospective study was performed to establish whether infection with specific hepatitis C virus (HCV) genotypes was associated with an increased risk of development of hepatocellular carcinoma (HCC) in cirrhosis. A cohort of 163 consecutive hepatitis C virus antibody (anti-HCV)-positive cirrhotic patients was prospectively evaluated for the development of HCC at 6-month intervals by ultrasound (US) scan and alpha-fetoprotein (AFP) concentration. HCV genotypes were determined according to Okamoto. Risk factors associated with cancer development were analyzed by univariate and multivariate statistics. At enrollment, 101 patients (62%) were infected with type 1b, 48 (29.5%) were infected with type 2a/c, 2 (1.2%) were infected with type 3a, 1 (0.6%) was infected with type 1a, 3 (1.8%) had a mixed-type infection, and, in 8 patients (4.9%), genotype could not be assigned. After a 5- to 7-year follow-up (median, 68 months), HCC developed in 22 of the patients, 19 infected with type 1b and 3 with type 2a/c (P < .005). Moreover, HCC developed more frequently in males (P < .01), patients with excessive alcohol intake (P < .01), those over 60 years of age (P < .02), and in patients who did not receive interferon treatment (P < .02). Multivariate analysis showed that type 1b was the most important risk factor associated with tumor development (odds ratio 6.14, 1.77-21.37 95% confidence interval). Other independent risk factors were older age and male sex. Cirrhotic patients infected with HCV type 1b carry a significantly higher risk of developing HCC than patients infected by other HCV types. The latter may require a less intensive clinical surveillance for the early detection of neoplasia.

PubMed Disclaimer

Comment in

• Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma.
  Brechot C. Brechot C. Hepatology. 1997 Mar;25(3):772-4. doi: 10.1002/hep.510250347. Hepatology. 1997. PMID: 9049234 No abstract available.
• Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma.
  Romeo R, Rumi MG, Del Ninno E, Colombo M. Romeo R, et al. Hepatology. 1997 Oct;26(4):1077. doi: 10.1002/hep.510260443. Hepatology. 1997. PMID: 9328339 No abstract available.

Similar articles

• Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b.
  Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA, Wendt NK, Mitchell PS, Germer JJ, Persing DH. Zein NN, et al. Am J Gastroenterol. 1996 Dec;91(12):2560-2. Am J Gastroenterol. 1996. PMID: 8946986
• Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.
  Chen DS. Chen DS. Princess Takamatsu Symp. 1995;25:27-32. Princess Takamatsu Symp. 1995. PMID: 8875606 Review.
• Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
  Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C. Mazziotti G, et al. Cancer. 2002 Dec 15;95(12):2539-45. doi: 10.1002/cncr.11002. Cancer. 2002. PMID: 12467068
• Hepatocellular carcinoma and hepatitis C in the United States.
  El-Serag HB. El-Serag HB. Hepatology. 2002 Nov;36(5 Suppl 1):S74-83. doi: 10.1053/jhep.2002.36807. Hepatology. 2002. PMID: 12407579 Review.

Cited by

• Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials.
  Kimer N, Dahl EK, Gluud LL, Krag A. Kimer N, et al. BMJ Open. 2012 Oct 22;2(5):e001313. doi: 10.1136/bmjopen-2012-001313. Print 2012. BMJ Open. 2012. PMID: 23089208 Free PMC article.
• Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.
  Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Young AM, et al. J Med Virol. 2012 Sep;84(9):1376-87. doi: 10.1002/jmv.23252. J Med Virol. 2012. PMID: 22825816 Free PMC article.
• Global Inequities in Precision Medicine and Molecular Cancer Research.
  Drake TM, Knight SR, Harrison EM, Søreide K. Drake TM, et al. Front Oncol. 2018 Sep 4;8:346. doi: 10.3389/fonc.2018.00346. eCollection 2018. Front Oncol. 2018. PMID: 30234014 Free PMC article. Review.
• Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma?
  Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, Tang J, Anderson M, Misra S, Solomon NL, Jin X, DiPasco PJ, Byrne MM, Zimmers TA. Koniaris LG, et al. Ann Surg. 2011 Sep;254(3):527-37; discussion 537-8. doi: 10.1097/SLA.0b013e31822ca66f. Ann Surg. 2011. PMID: 21865950 Free PMC article.
• Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
  Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Yuen MF, et al. Dig Dis Sci. 2021 Apr;66(4):1315-1326. doi: 10.1007/s10620-020-06281-8. Epub 2020 May 8. Dig Dis Sci. 2021. PMID: 32385703 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information